Biocon insulin operation gets FDA nod, paving way for approval of Lantus knockoff

Biocon Malaysia insulin plant
Biocon's insulin production operation in Malaysia has now passed FDA muster ahead of a June target action date for potential approval of a Lantus copy developed by it and Mylan. (Biocon)

Biocon has finally satisfied the FDA that its insulin production plant in Malaysia is ready for prime time. The sign-off on the plant opens the way for a possible approval of the Lantus competitor developed with Mylan, which has been delayed in the U.S. for several years because of manufacturing questions. 

Biocon reported (PDF) Wednesday the FDA has closed the pre-inspection of the plant for its insulin glargine, tagging the facility with a voluntary action indicated, a rating that indicates the facility meets at least the minimum FDA standards. 

The finding follows a February inspection that resulted in a Form 483 with three observations. Biocon called the FDA decision “an endorsement of our commitment to global standards of Quality and Compliance.” 

Cambrex Webinar

Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays

Wednesday, May 27, 2020 | 10am ET / 7am PT

A well-developed crystallization process can produce suitable particles that can facilitate consistent filtration, drying and formulation of the API and allow confident and reliable manufacturing of the final drug product, while avoiding unnecessary cost, risk and development delays.

RELATED: Biocon confident of approval for Lantus copy after Malaysia plant inspected by FDA a 3rd time

Mylan’s application for the knockoff of Sanofi’s blockbuster is currently before the FDA for review with a June target action date. Biocon and Mylan have won approval of their drug, branded Semglee, in Europe and some other markets, where it competes with other knockoffs.

It's been a long and bumpy road for the candidate, which has twice been sidelined by complete response letters because of the FDA’s concerns over the Malaysia plant. The second CRL was issued last August after the FDA tallied a dozen issues during a June pre-approval inspection of the three facilities that comprise the manufacturing operation for the drug.  

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.